AU2018338178B2 - Glucagon-like peptide 1 receptor agonists and uses thereof - Google Patents

Glucagon-like peptide 1 receptor agonists and uses thereof Download PDF

Info

Publication number
AU2018338178B2
AU2018338178B2 AU2018338178A AU2018338178A AU2018338178B2 AU 2018338178 B2 AU2018338178 B2 AU 2018338178B2 AU 2018338178 A AU2018338178 A AU 2018338178A AU 2018338178 A AU2018338178 A AU 2018338178A AU 2018338178 B2 AU2018338178 B2 AU 2018338178B2
Authority
AU
Australia
Prior art keywords
glp1
ser
val
lys
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018338178A
Other languages
English (en)
Other versions
AU2018338178A1 (en
Inventor
Samuel Davis
Jesper Gromada
Andrew J. Murphy
Haruka Okamoto
Yang Wei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of AU2018338178A1 publication Critical patent/AU2018338178A1/en
Application granted granted Critical
Publication of AU2018338178B2 publication Critical patent/AU2018338178B2/en
Priority to AU2023223010A priority Critical patent/AU2023223010B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
AU2018338178A 2017-09-22 2018-09-21 Glucagon-like peptide 1 receptor agonists and uses thereof Active AU2018338178B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023223010A AU2023223010B2 (en) 2017-09-22 2023-09-04 Glucagon-like peptide 1 receptor agonists and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762562283P 2017-09-22 2017-09-22
US62/562,283 2017-09-22
PCT/US2018/052110 WO2019060653A1 (en) 2017-09-22 2018-09-21 GLP-1 RECEPTOR AGONISTS (GLUCAGON-LIKE PEPTIDE 1) AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023223010A Division AU2023223010B2 (en) 2017-09-22 2023-09-04 Glucagon-like peptide 1 receptor agonists and uses thereof

Publications (2)

Publication Number Publication Date
AU2018338178A1 AU2018338178A1 (en) 2020-04-02
AU2018338178B2 true AU2018338178B2 (en) 2023-06-08

Family

ID=63799082

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018338178A Active AU2018338178B2 (en) 2017-09-22 2018-09-21 Glucagon-like peptide 1 receptor agonists and uses thereof
AU2023223010A Active AU2023223010B2 (en) 2017-09-22 2023-09-04 Glucagon-like peptide 1 receptor agonists and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023223010A Active AU2023223010B2 (en) 2017-09-22 2023-09-04 Glucagon-like peptide 1 receptor agonists and uses thereof

Country Status (14)

Country Link
US (4) US11045522B2 (enExample)
EP (1) EP3684793A1 (enExample)
JP (2) JP7239566B2 (enExample)
KR (1) KR102696518B1 (enExample)
CN (2) CN111108117B (enExample)
AU (2) AU2018338178B2 (enExample)
CA (1) CA3073964A1 (enExample)
EA (1) EA202090649A1 (enExample)
IL (2) IL304574B2 (enExample)
MX (1) MX2020002977A (enExample)
MY (2) MY200364A (enExample)
SG (1) SG11202001637PA (enExample)
WO (1) WO2019060653A1 (enExample)
ZA (1) ZA202001167B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7239566B2 (ja) * 2017-09-22 2023-03-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用
US12122817B2 (en) * 2020-09-22 2024-10-22 Serpentide Inc. Long-lasting GLP1 analogue drug for type-2 diabetes
WO2022117044A1 (en) * 2020-12-03 2022-06-09 Sunshine Lake Pharma Co., Ltd. Glp-1/gcg dual receptor agonist polypeptide and fusion protein thereof
KR102828488B1 (ko) * 2020-12-03 2025-07-02 이뮤노포지 주식회사 Glp-1 수용체 작용제 및 항-오스카 항체를 포함하는 융합 단백질 및 이의 용도
CN112716966B (zh) * 2021-02-03 2022-05-03 浙江诺得药业有限公司 一种恩格列净药用组合物及其制备方法
CN113461785B (zh) * 2021-04-13 2022-10-14 湖南中晟全肽生化有限公司 Glp-1受体激动剂及其应用
CN114874333B (zh) * 2021-10-18 2025-01-24 深圳科兴药业有限公司 一种生长激素融合蛋白及其应用
CN114788876B (zh) * 2022-02-24 2024-07-05 北京医院 治疗糖尿病的mRNA药物制剂及其制备方法与应用
KR20230156889A (ko) * 2022-05-04 2023-11-15 이뮤노포지 주식회사 GLP-1, 면역글로불린 Fc, 및 IGF-1을 포함하는 융합단백질 및 이의 용도
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
CN117143242B (zh) * 2023-10-30 2024-03-29 南京佰抗生物科技有限公司 抗Galectin-3蛋白的单克隆抗体组合物及应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
US20250270274A1 (en) * 2024-02-26 2025-08-28 Serpentide Inc. Super long-lasting glp1 or glp1/gip analogue drug for type-2 diabetes and obesity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101229610B1 (ko) * 2009-10-09 2013-02-05 한남대학교 산학협력단 Ｇｌｐ-1 유사체의 융합체, 및 이를 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 조성물
CN104098702A (zh) * 2014-07-23 2014-10-15 湖北工业大学 一种利用mfh融合蛋白制备glp-1多肽或其类似物方法和应用
EP3034514A1 (en) * 2013-08-13 2016-06-22 Gmax Biopharm LLC Antibody specifically binding to glp-1r and fusion protein thereof with glp-1

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ543292A (en) 2003-06-12 2008-04-30 Lilly Co Eli GLP-1 analog fusion proteins
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US20060275288A1 (en) 2005-01-20 2006-12-07 Grihalde Nelson D GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
AR064623A1 (es) 2006-12-21 2009-04-15 Centocor Inc Uso de agonistas del receptor de glp -1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
JP2010535781A (ja) 2007-08-03 2010-11-25 イーライ リリー アンド カンパニー 肥満に対する処置
JP5476304B2 (ja) 2007-09-05 2014-04-23 ノボ・ノルデイスク・エー／エス グルカゴン様ペプチド−１誘導体及びそれらの医薬用途
SI2373681T1 (sl) 2008-12-10 2017-05-31 Glaxosmithkline Llc Corporation Service Company Farmacevtski sestavki albiglutida
US20120148586A1 (en) 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
WO2011056644A2 (en) 2009-10-28 2011-05-12 Centocor Ortho Biotech Inc. Anti-glp-1r antibodies and their uses
US20120294855A1 (en) 2009-11-03 2012-11-22 Eli Lilly & Company Glp-1 receptor agonist compounds for obstructive sleep apnea
BR112015004734A2 (pt) 2012-09-07 2017-11-21 Sanofi Sa proteínas de fusão para tratar uma síndrome metabólica
MX366685B (es) 2013-01-17 2019-07-19 Vtv Therapeutics Llc Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos.
US20150259416A1 (en) 2014-03-12 2015-09-17 Biocrine Ab Methods for treating and/or limiting development of diabetes
CN106390100B (zh) * 2015-01-28 2021-06-22 中国科学院天津工业生物技术研究所 一种多肽复合物作为glp-1药物载体的应用、方法及其融合蛋白复合物
ES2833099T3 (es) 2015-02-11 2021-06-14 Gmax Biopharm Llc Preparación de disolución estabilizada de una proteína de fusión de un anticuerpo de GLP-1R farmacéutica
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
JP2019525732A (ja) * 2016-06-09 2019-09-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ プロテアーゼ耐性一脂質付加ペプチド
JP7239566B2 (ja) 2017-09-22 2023-03-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101229610B1 (ko) * 2009-10-09 2013-02-05 한남대학교 산학협력단 Ｇｌｐ-1 유사체의 융합체, 및 이를 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 조성물
EP3034514A1 (en) * 2013-08-13 2016-06-22 Gmax Biopharm LLC Antibody specifically binding to glp-1r and fusion protein thereof with glp-1
CN104098702A (zh) * 2014-07-23 2014-10-15 湖北工业大学 一种利用mfh融合蛋白制备glp-1多肽或其类似物方法和应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HYE-SHIN CHUNG, JI-YEON OH, SEUNG-BUM YOO, SANG MEE LEE, HEUNG-SOO CHO: "The N-terminal alanine-extended GLP-1/IgG-Fc fusion protein confers resistance to DPP-IV and reduces serum glucose level in db/db mice", REGULATORY PEPTIDES, ELSEVIER SCIENCE BV, NL, vol. 170, no. 1-3, 1 October 2011 (2011-10-01), NL , pages 1 - 3, XP055523607, ISSN: 0167-0115, DOI: 10.1016/j.regpep.2011.05.002 *
YONG-MO KIM, SANG MEE LEE, HYE-SHIN CHUNG: "Novel AGLP-1 albumin fusion protein as a long-lasting agent for type 2 diabetes", BMB REPORTS, KOREAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, KR, vol. 46, no. 12, 31 December 2013 (2013-12-31), KR , pages 606 - 610, XP055523611, ISSN: 1976-6696, DOI: 10.5483/BMBRep.2013.46.12.106 *

Also Published As

Publication number Publication date
CN111108117B (zh) 2024-08-06
KR102696518B1 (ko) 2024-08-21
KR20200054303A (ko) 2020-05-19
AU2023223010A1 (en) 2023-11-09
EP3684793A1 (en) 2020-07-29
CN111108117A (zh) 2020-05-05
IL273253B2 (en) 2024-07-01
ZA202001167B (en) 2024-06-26
WO2019060653A1 (en) 2019-03-28
CN118955732A (zh) 2024-11-15
US20190091296A1 (en) 2019-03-28
IL273253B1 (en) 2024-03-01
US12090193B2 (en) 2024-09-17
CA3073964A1 (en) 2019-03-28
JP7559112B2 (ja) 2024-10-01
US20210283225A1 (en) 2021-09-16
MY207828A (en) 2025-03-21
SG11202001637PA (en) 2020-03-30
JP2024178255A (ja) 2024-12-24
JP7239566B2 (ja) 2023-03-14
US11779633B2 (en) 2023-10-10
EA202090649A1 (ru) 2020-06-29
IL273253A (en) 2020-04-30
AU2023223010B2 (en) 2025-12-04
US11045522B2 (en) 2021-06-29
MY200364A (en) 2023-12-21
JP2023071827A (ja) 2023-05-23
AU2018338178A1 (en) 2020-04-02
JP2020534016A (ja) 2020-11-26
IL304574A (en) 2023-09-01
IL304574B2 (en) 2025-08-01
MX2020002977A (es) 2020-11-06
US20240024428A1 (en) 2024-01-25
IL304574B1 (en) 2025-04-01
US20250000949A1 (en) 2025-01-02

Similar Documents

Publication Publication Date Title
AU2023223010B2 (en) Glucagon-like peptide 1 receptor agonists and uses thereof
EP3570885B1 (en) Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
EP3331908B1 (en) Anti-angptl8 antibodies and uses thereof
AU2017363143B2 (en) Methods of treating obesity with anti-ANGPTL8 antibodies
JP7789871B2 (ja) グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用
US12122817B2 (en) Long-lasting GLP1 analogue drug for type-2 diabetes
WO2025180387A1 (en) Super long-lasting glp1 or glp1/gip analogue drugfor type-2 diabetes and obesity
EA045412B1 (ru) Агонисты рецептора глюкагоноподобного пептида 1 и их применения
HK40017935B (en) Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
HK40017935A (en) Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)